US › Healthcare

IRulya Therapeutics Inc. (IRLA)

US · Healthcare · Biotechnology

$31.00+5.77%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-75.5M

EPS

$-12.15

EPS estimate

$-12.39

EPS came in at -12.15 against a street estimate of -12.39 — a beat of 1.9%.

Key statistics

Market cap

$29.8M

Forward P/E

0.0

P/B

2.21

Book value

$-34.73

EPS (TTM)

$-214.01

52-week high

$910.00

52-week low

$15.10

50-day MA

$31.07

200-day MA

$45.10

Beta

1.79

Analyst view

Analysts rate IRulya Therapeutics Inc. a strong buy (8 buy, 1 hold, 0 sell out of 9) with an average price target of $75.00.

Shareholding

Insiders

0.27%

Institutions

11.66%

Largest institutional holders

Fund	Stake
Ikarian Capital, LLC	0.36%
Millennium Management LLC	0.35%
Balyasny Asset Management LLC	0.34%
Squadron Capital Management LLC	0.20%
Shay Capital LLC	0.09%
BOOTHBAY FUND MANAGEMENT, LLC	0.07%
Jane Street Group LLC	0.06%
Vanguard Capital Management, LLC	0.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for IRulya Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.